An Evidence Review Group Perspective of a NICE Highly Specialised Technology Appraisal: VN for RPE65-mediated IRD

In collaboration with the Peninsula Technology Assessment Group (PenTAG, University of Exeter), Delta Hat’s Ash Bullement and Anthony Hatswell are co-authors on a recent article published in Pharmacoeconomics.

The article summarises the Evidence Review Group’s perspective on a recent Highly Specialised Technology (HST) appraisal conducted by NICE of voretigene neparvovec (a gene therapy for people with a very rare inherited eye disorder).

You can read the article by following this link: